

Selenium Slows Down Autoimmune Thyroiditis

BY PATRICE WENDLING
Chicago Bureau

VERONA, ITALY — For the first time, selenium supplementation has been shown to lessen the progression of autoimmune chronic thyroiditis in pregnant women.

Pregnant women who are positive for thyroid peroxidase antibodies are prone to develop postpartum thyroid dysfunction and permanent hypothyroidism.

Selenium supplementation during and after pregnancy reduced the incidence of both conditions in a large prospective, randomized controlled trial of euthyroid



'Adequate selenium supplementation may reduce the inflammatory action of the thyroid gland after delivery.'

DR. NEGRO

pregnant women, Dr. Roberto Negro and associates reported in an award-winning poster at a joint meeting of the Italian Association of Clinical Endocrinologists and the American Association of Clinical Endocrinologists.

"Giving adequate selenium supplementation may reduce the inflammatory action of the thyroid gland after delivery," Dr. Negro said in an interview. "This is not sufficient to recommend this treatment for all pregnant women affected by chronic autoimmune thyroiditis, but it may be considered."

Of the 2,143 women who participated in the study, 8% were positive for thyroid peroxidase antibodies (TPOAb). Of the TPOAb-positive women who remained in the study and who did not miscarry, Dr. Negro and associates randomized 77 to 200 mcg/day selenomethionine beginning at the 12th week of pregnancy until 12 months after delivery, and 74 to placebo. Of the TPOAb-negative women, 81 were age matched and served as the control. Thyroid function tests were performed at 20 and 30 weeks' gestation, at delivery, and after delivery at months 1, 2, 5, 9, and 12.

Blood selenium concentrations were measured at the first endocrinologic visit (at an average 9.4 weeks' gestation), at 20 and 30 weeks' gestation, at delivery, and at 6 and 12 months after delivery. Thyroid ultrasound scans were performed by an independent radiologist at the first endocrinologic visit during pregnancy, at delivery, and at 12 months after delivery.

At baseline, there were no significant differences between the three groups in average age (28 years, 28 years, and 27 years, respectively), in free thyroxine levels, and in the time supplementation began (average 12 weeks).

Significant differences were noted between groups in baseline thyroid-stimulating hormone (1.6 mIU/L, 1.7 mIU/L, and 0.9 mIU/L, respectively) and in those requiring levothyroxine during pregnancy

(19.4%, 21.6%, and 2.5%, respectively).

At 12 months after delivery, rates of postpartum thyroid dysfunction (28.6% vs. 48.6%) and permanent hypothyroidism (11.7% vs. 20.3%) were significantly lower in women taking the selenium supplements than in placebo-treated patients, the authors reported.

In addition, TPOAb titers were significantly lower in the supplement group compared with placebo-treated patients, with a 62.4% versus 43.9% reduction during preg-

nancy and lower titers during the postpartum period (323.2 kIU/L vs. 621.1 kIU/L).

When the ultrasound echogenicity patterns of the two groups were compared, the selenium-supplemented group displayed a significantly lower percentage of moderate to advanced thyroiditis (grades 2-3) at the end of the postpartum period (27.3% vs. 44.6%), the authors reported.

No side effects were reported in the mothers and no families have been recalled for newborn thyroid dysfunction,

said Dr. Negro, of the endocrinology department at Azienda Ospedaliera "Vito Fazzi," Lecce, Italy.

"Relatively high doses are needed to obtain a significant response on postpartum thyroid dysfunction," he said.

Further investigations are required to know whether these beneficial effects are reversed if selenium supplementation is interrupted or whether they can be maintained for a long time if selenium is continued, the authors concluded. ■

Discover Levemir®:
a long-acting basal insulin
with a light touch

Levemir: for your patients who need a safe and effective way to improve A1C control

With proven reductions in A1C and FPG levels over time, Levemir can help your patients get to goal with up to 24 hours of glycemic control. Patients with diabetes can experience a consistent blood glucose response from injection to injection. Less weight gain was observed with Levemir in 12 of 12 clinical trials.* And Levemir is available in the Levemir® FlexPen®. FlexPen® is the world's #1 selling prefilled insulin pen.† So start your patients with diabetes on Levemir, and help them experience the light side of basal insulin.

Levemir is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

Important safety information
Levemir should not be diluted or mixed with any other insulin preparations.

Levemir is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

Levemir is not to be used in insulin infusion pumps. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir from other intermediate or long-acting insulin preparations. The dose of Levemir may need to be adjusted in patients with renal or hepatic impairment.

Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation.

*Whether these observed differences represent true differences in the effects of Levemir and NPH insulin is not known, since these trials were not blinded and the protocols (eg, diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

Reference: 1. IMS Health, IMS MIDAS [12 months ending September 2005]. Please see brief summary of Prescribing Information on adjacent page. FlexPen and Levemir are registered trademarks of Novo Nordisk A/S. © 2006 Novo Nordisk Inc. 131007 September 2006

Levemir®
insulin detemir (rDNA origin) injection
Lighter years ahead